CN105228618A - 用于选择性杀死癌细胞的trail增强剂 - Google Patents

用于选择性杀死癌细胞的trail增强剂 Download PDF

Info

Publication number
CN105228618A
CN105228618A CN201480028681.0A CN201480028681A CN105228618A CN 105228618 A CN105228618 A CN 105228618A CN 201480028681 A CN201480028681 A CN 201480028681A CN 105228618 A CN105228618 A CN 105228618A
Authority
CN
China
Prior art keywords
tumor
alkenyl
compound
alkynyl
trail
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480028681.0A
Other languages
English (en)
Chinese (zh)
Inventor
弗拉迪米尔·克拉夫琴科
理查德·J·乌莱维特
基姆·D·扬达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CN105228618A publication Critical patent/CN105228618A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480028681.0A 2013-03-19 2014-03-19 用于选择性杀死癌细胞的trail增强剂 Pending CN105228618A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361803177P 2013-03-19 2013-03-19
US61/803,177 2013-03-19
PCT/US2014/031235 WO2014153415A2 (en) 2013-03-19 2014-03-19 Trail enhancers for the selective killing of cancer cells

Publications (1)

Publication Number Publication Date
CN105228618A true CN105228618A (zh) 2016-01-06

Family

ID=51581796

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480028681.0A Pending CN105228618A (zh) 2013-03-19 2014-03-19 用于选择性杀死癌细胞的trail增强剂

Country Status (8)

Country Link
US (2) US9604950B2 (https=)
EP (1) EP2976076B1 (https=)
JP (1) JP6307149B2 (https=)
KR (2) KR101819874B1 (https=)
CN (1) CN105228618A (https=)
AU (1) AU2014236003A1 (https=)
CA (1) CA2907668C (https=)
WO (1) WO2014153415A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105504000A (zh) * 2016-01-21 2016-04-20 福建农林大学 一种筛选n-酰基高丝氨酸内酯类模拟物的方法
US9604950B2 (en) 2013-03-19 2017-03-28 The Scripps Research Institute Trail enhancers for the selective killing of cancer cells
CN110935012A (zh) * 2019-12-19 2020-03-31 东北师范大学 一种用于治疗肿瘤的药物组合物
CN111110867A (zh) * 2016-06-03 2020-05-08 国家农艺研究院 编码促凋亡蛋白的核酸的膳食受控表达

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195177B2 (en) 2015-10-01 2019-02-05 The University Of Toledo Use of acyl-homoserine lactone derivatives as anti-thrombotic agents
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259942A1 (en) * 2001-09-22 2004-12-23 Peter Shaw Modulation of stat activity
US20070010488A1 (en) * 2005-04-13 2007-01-11 Khairia Youssef Compounds for modulating cell proliferation
CN102482244A (zh) * 2009-07-03 2012-05-30 内盖夫国家生物技术有限公司 细菌群体感应的共价抑制

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924195D0 (en) * 1999-10-13 1999-12-15 Univ Nottingham N-Acyl homoserine lactones for the treatment of cardiac tachyarrhythmias Ischaemic heart disease or congestive heart failure
JP2004231556A (ja) * 2003-01-29 2004-08-19 Nobuhiko Nomura アポトーシス誘導剤
WO2004075839A2 (en) * 2003-02-21 2004-09-10 Irm Llc Methods and compositions for modulating apoptosis
US20070010477A1 (en) * 2005-04-07 2007-01-11 Dolnick Bruce J Acyl homoserine lactones for inhibition of cell growth
GB0610042D0 (en) * 2006-05-22 2006-06-28 Univ Nottingham Substituted n-acyl homoserine lactones
EP2976076B1 (en) 2013-03-19 2020-03-04 The Scripps Research Institute Trail enhancers for the selective killing of cancer cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040259942A1 (en) * 2001-09-22 2004-12-23 Peter Shaw Modulation of stat activity
US20070010488A1 (en) * 2005-04-13 2007-01-11 Khairia Youssef Compounds for modulating cell proliferation
CN102482244A (zh) * 2009-07-03 2012-05-30 内盖夫国家生物技术有限公司 细菌群体感应的共价抑制

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AMANDA L. GARNER ET AL.: "Synthesis of ‘clickable’ acylhomoserine lactone quorum sensing probes:Unanticipated effects on mammalian cell activation", 《BIOORG. MED. CHEM. LETT.》 *
LUBA DUBINSKY ET AL.: "Synthesis and validation of a probe to identify quorum sensing receptors", 《CHEM. COMMUN.》 *
THANIT PRANEENARARAT等: "Chemical methods to interrogate bacterial quorum sensing pathways", 《ORGANIC & BIOMOLECULAR CHEMISTRY》 *
VLADIMIR KRAVCHENKO ET AL.: "Facilitating Cytokine-Mediated Cancer Cell Death by Proteobacterial N‑Acylhomoserine Lactones", 《ACS CHEMICAL BIOLOGY》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9604950B2 (en) 2013-03-19 2017-03-28 The Scripps Research Institute Trail enhancers for the selective killing of cancer cells
US9765061B2 (en) 2013-03-19 2017-09-19 The Scripps Research Institute Trail enhancers for the selective killing of cancer cells
CN105504000A (zh) * 2016-01-21 2016-04-20 福建农林大学 一种筛选n-酰基高丝氨酸内酯类模拟物的方法
CN111110867A (zh) * 2016-06-03 2020-05-08 国家农艺研究院 编码促凋亡蛋白的核酸的膳食受控表达
CN110935012A (zh) * 2019-12-19 2020-03-31 东北师范大学 一种用于治疗肿瘤的药物组合物

Also Published As

Publication number Publication date
KR101819874B1 (ko) 2018-01-17
US9765061B2 (en) 2017-09-19
KR101743383B1 (ko) 2017-06-02
US20160272603A1 (en) 2016-09-22
US20170101400A1 (en) 2017-04-13
US9604950B2 (en) 2017-03-28
EP2976076A4 (en) 2016-11-16
EP2976076B1 (en) 2020-03-04
CA2907668C (en) 2021-02-23
JP2016515546A (ja) 2016-05-30
CA2907668A1 (en) 2014-09-25
WO2014153415A3 (en) 2015-01-08
JP6307149B2 (ja) 2018-04-04
WO2014153415A2 (en) 2014-09-25
KR20150135387A (ko) 2015-12-02
KR20170063980A (ko) 2017-06-08
AU2014236003A1 (en) 2015-11-05
EP2976076A2 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
CN105228618A (zh) 用于选择性杀死癌细胞的trail增强剂
US11154531B2 (en) Compounds and pharmaceutical uses thereof
JP2021193093A (ja) Ｍａｌｔ１阻害剤およびその使用
US20190002429A1 (en) Derivatives of Xanthone Compounds
TW201039815A (en) Compositions and methods for the treatment of inflammation
EP2696864A1 (en) Therapeutic compounds
CN105682655A (zh) 抗微生物化合物
JP2020530477A (ja) Ｎｒ４ａ１リガンド、医薬組成物、及び関連する使用方法
JP6617702B2 (ja) Ｆｔｙ７２０のアザサイクリック拘束アナログ
CN106562951B (zh) 一种呋喃类d-3-磷酸甘油酸脱氢酶别构抑制剂及其应用
BR112019010816A2 (pt) composto de fórmula i, composto de fórmula ii, composto de fórmula iii, composto de fórmula iv, composto de fórmula v, composição farmacêutica, compostos, composto de fórmula viii, composto de fórmula ix, e composto de fórmula x
JP2015505536A (ja) 疾患の処置のための置換された複素環化合物
KR102235994B1 (ko) 환상 아민 유도체의 결정 및 그 의약 용도
US8853452B2 (en) Compounds, their syntheses, compositions, and methods to treat cancer
KR20050004155A (ko) 선택적 유도성 산화질소 신타아제 억제제를 이용한 호흡기질병 및 질환의 치료 방법
JP2011530539A (ja) 腫瘍形成を抑制する脂質化合物
CN115836062A (zh) 化合物及其医药用途
WO2016066115A1 (zh) 取代杂环衍生物、其制备方法和用途
US20170260134A1 (en) Ceramide Analogs
TW202535345A (zh) １０，１１－二氟－１２－（（２－氟－４－碘苯基）胺基）－５，６－二羥基－４，５，６，７－四氫－１ｈ－螺［苯并［ｂ］［１，５，４］氧雜噻西啶－３，１＇－環丙烷］ ２，２－二氧化物 立體異構物以及包含其之組合物及使用其之方法
US20210139435A1 (en) Prostaglandin analogs and uses thereof
TW202440134A (zh) 新穎小分子kras抑制劑：為難成藥標的提供藥物用於癌症治療
WO2025079163A1 (ja) ４－（２，４－ジフルオロフェニル）－２－（１ｈ－インドール－３－イル）－４－オキソ－ブタン酸のｓ（＋）体
JP2025533301A (ja) 新規の治療用分子
OA21266A (en) Dicarboxylic acid esters for inducing an analgesic effect.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20181023